Home/Nurix Therapeutics/Stephanie Hua
SH

Stephanie Hua

Chief Legal Officer & Corporate Secretary

Nurix Therapeutics

Nurix Therapeutics Pipeline

DrugIndicationPhase
Bexobrutideg (NX-5948)Relapsed/Refractory B-cell MalignanciesPhase 1a/1b
NX-2127Relapsed/Refractory B-cell MalignanciesPhase 1a
NX-1607Oncology & Autoimmune IndicationsPhase 1
NX-0479Immuno-inflammatory DiseasesPhase 1
NX-0451Solid TumorsPreclinical
NX-0370Solid TumorsPreclinical
NX-0290Solid TumorsPreclinical